|
Post by lennymnkd on Mar 29, 2018 19:38:02 GMT -5
Hope I’m wrong ! But I believe Mike said it would not be a substantial sum . Just the opposite.
|
|
|
Post by InvesterSam on Mar 29, 2018 20:39:03 GMT -5
Hope I’m wrong ! But I believe Mike said it would not be a substantial sum . Just the opposite. Q4 CC Mike C "Additionally, we have a fine term sheet for a large market upsize U.S. and when the process of finalizing a second term sheet. One of both is we hope to announce in the first of this year but as you know, these things take time. We do expect these deal structures will have a combination of upfront milestones royalties and more importantly we need to continue to serve patients around the world - well we know these markets may not generate a lot of cash, they will tremendously make a difference for society, and I believe with the 80 million to 100 million people in some of these markets, who haven't [indiscernible] just a minor share in these segments will offset a tremendous difference in people's lives."
|
|
|
Post by mnholdem on Mar 29, 2018 21:29:09 GMT -5
Hope I’m wrong ! But I believe Mike said it would not be a substantial sum . Just the opposite. Q4 CC Mike C "Additionally, we have a fine term sheet for a large market upsize U.S. and when the process of finalizing a second term sheet. One of both is we hope to announce in the first of this year but as you know, these things take time. We do expect these deal structures will have a combination of upfront milestones royalties and more importantly we need to continue to serve patients around the world - well we know these markets may not generate a lot of cash, they will tremendously make a difference for society, and I believe with the 80 million to 100 million people in some of these markets, who haven't [indiscernible] just a minor share in these segments will offset a tremendous difference in people's lives." Seeking Alpha transcripts are typically horrendous and they always seem to butcher MannKind conference calls in particular. I'm not saying they do it intentionally...it might be that MannKind is such a small biotechnology company that they don't put their best people to the task. I think the transcript should have been written as follows: " We do expect these deal structures will have a combination of upfront, milestones, royalties and, more importantly, we need to continue to serve patients around the world..."Adding a few punctuation marks makes a huge difference to context.
|
|
|
Post by dreamboatcruise on Mar 30, 2018 3:48:22 GMT -5
Q4 CC Mike C "Additionally, we have a fine term sheet for a large market upsize U.S. and when the process of finalizing a second term sheet. One of both is we hope to announce in the first of this year but as you know, these things take time. We do expect these deal structures will have a combination of upfront milestones royalties and more importantly we need to continue to serve patients around the world - well we know these markets may not generate a lot of cash, they will tremendously make a difference for society, and I believe with the 80 million to 100 million people in some of these markets, who haven't [indiscernible] just a minor share in these segments will offset a tremendous difference in people's lives." Seeking Alpha transcripts are typically horrendous and they always seem to butcher MannKind conference calls in particular. I'm not saying they do it intentionally...it might be that MannKind is such a small biotechnology company that they don't put their best people to the task. I think the transcript should have been written as follows: " We do expect these deal structures will have a combination of upfront, milestones, royalties and, more importantly, we need to continue to serve patients around the world..."Adding a few punctuation marks makes a huge difference to context. Yes, punctuation makes a lot of difference, hence very ambiguous as to whether it is "upfront, milestones, royalties" or "upfront milestones, royalties", as any payment before revenue might be considered upfront... who knows... not me. Though perhaps revealing that, "more importantly... ". Which I'm ok with as well. I will be very impressed if the deal that already has a finalized term sheet (per Mike) has a meaningful immediate upfront payment.
|
|
|
Post by psquare on Mar 30, 2018 9:28:21 GMT -5
I do not post often because I cann't tell the difference between mango and tango when it comes to investing. So I keep quiet and just listen to the experts. You folks amaze me with your knowledge and dedication. I do not know if any message board can come close to providing the quality of the conversations on this board. Please keep it up. The Mannkind and Afrezza story is one for the record books.
If I may, can I rearrange the sentence to read: "We do expect these deal structures will have a combination of upfront royalties, milestone royalties and, more importantly, we need to continue to serve patients around the worls...."
|
|
|
Post by MnkdWASmyRtrmntPlan on Mar 30, 2018 9:39:46 GMT -5
Right, DBC. I am very happy we have Mike as CEO, however, he does have a choppy delivery of his presentations at times. I do kind of wish he would read from a pre-written script more than he seems to do. That paragraph is a good example of the confusion it can create. But, then again, perhaps that's by his design.
In any case, someone on PB mentioned recently that there will be no good news until the June ADA STAT Study announcement. I have to believe that these forthcoming announcements of the developments of these two term sheets will be very good news, and they will prove very beneficial to the SP. Dilution is already baked into the current stock price, and that news will eliminate the fear of the unknown, which always puts downward pressure on SP.
I believe what Mike meant to say is "we have a fine term sheet for a large U.S. market upsize." That sounds pretty good to me. Although I am not sure how you could upsize the US market. The market size is what it is. He either means to increase our market penetration, or it could be considered to upsize the diabetes market by adding pre-diabetes patients. Either way sounds good to me. The sticky point is how will Mike arrange the required capital ... but, Mike has been operating with the investors' best interests in mind. I would just love to see another $6.00 surprise like last October.
I believe Mike also meant to say "We hope to announce one or both in the first quarter of this year, but as you know, these things take time." So, there are just a few more hours to announce them in the first quarter. Hopefully, they will at least come early in the second quarter. I know in my heart that the SP will eventually hit the moon, but in the meantime, these $2 dollar prices are stressing me out.
|
|
|
Post by alethea on Mar 30, 2018 9:49:23 GMT -5
Anybody remember getting the new, approved label late last September?
Did we not have a thread shortly afterwards about hitting 600 scripts soon?
Struggling to hit 500 scrips 6 months after the much touted new label is a deep disappointment.
|
|
|
Post by straightly on Mar 30, 2018 10:01:53 GMT -5
Anybody remember getting the new, approved label late last September? Did we not have a thread shortly afterwards about hitting 600 scripts soon? Struggling to hit 500 scrips 6 months after the much touted new label is a deep disappointment. Sales are hard. I have yet to meet anybody we can predicate sales of new things with any accuracy. I did see many surprises, both positive and negative. The only approach I knew worked was throwing a few things against the wall and see what sticked. Here is hoping Mike found one.
|
|
|
Post by mnholdem on Mar 30, 2018 12:11:24 GMT -5
[Clipped] I believe what Mike meant to say is "we have a fine term sheet for a large U.S. market upsize." That sounds pretty good to me. Although I am not sure how you could upsize the US market. The market size is what it is. He either means to increase our market penetration, or it could be considered to upsize the diabetes market by adding pre-diabetes patients. Either way sounds good to me. The sticky point is how will Mike arrange the required capital ... but, Mike has been operating with the investors' best interests in mind. I would just love to see another $6.00 surprise like last October. [Clipped] I have forwarded literature to every CEO since Alfred Mann to support the strategy of a major study of using Afrezza for Short-Term Intensive Insulin (STII) therapy in trial patients with early Type 2 diabetes, which has had numerous studies over the past 15 years that prove it results in successful remission of diabetes in up to 50% of patients. "Pre-diabetes" is a misnomer, but that's another subject.
This is exactly the kind of trial that could be funded by both the federal government and private entities like the Gates Foundation. I spoke about the idea with an endocrinologist at the Mayo Clinic (a former next-door neighbor of mine). She liked the idea and also thought that it may be quite possible to get sufficient funding for such a major study.
What is problematic, from a pharmaceutical company's point of view, is that the therapy is exactly what it sounds like: Short-termed. If successful, the patient would need no more diabetes drugs. I can imagine that doesn't sit well with business executives, but I also pointed out that meeting the primary endpoint (remission) could propel Afrezza to the coveted First Line of Treatment in the ADA/AACE Diabetes Standard of Care. That would mean a massive increase in scripts. The beauty of the strategy, from a business perspective, is that patients who are not successful in achieving full remission would nonetheless become familiar with inhaled insulin, which could result in retention as prescriptions would continue for those patients whose pancreatic damage is too far along or who have other underlying causes.
It remains a major source of irritation that the ADA/AACE physicians are aware of these studies, but still they keep insulin as the very last treatment in their Standard of Care. I think that's largely because they see insulin as dangerous. Of course, they are thinking solely of injected insulin and lump Technosphere insulin in with the others or the failed inhaled insulin Exubera from years ago, which the educated among us know is not the same kind of insulin at all.
I would hope that Dr. Kendall is all aware of all the STII research and, if what you are suggesting - that Mike is indicating an expanded market with Afrezza for early-diabetes treatment - turns out to be correct, it would make me extremely excited as an investor.
I've even considered sending this idea to the President because he understands this kind of outside the box strategy and loves it. He recently announced that his administration will soon be taking aim at drug prices in the USA. I think the government would seriously consider funding STII because diabetes is reaching pandemic proportions and has become one of the most costly diseases in this country.
|
|
|
Post by buyitonsale on Mar 30, 2018 14:00:40 GMT -5
PWD who want to live longer are going to start using CGMs.
When they use CGM they will see their BG all the time.
When they see their BG all the time, they will start figuring out which drug keeps them in range better.
When they figure that out they will start using Affrezza for meals.
The question is, how many PWD want to live longer?
Answer - Should be all of them. So, no more studies are needed, just DTC advertising and telling doctors to wake up by showing everyone STAT study results.
|
|
|
Post by lennymnkd on Mar 30, 2018 14:25:03 GMT -5
Agree bios ! Getting people to care is the trick / universal marketing from diabetes foundations, etc ...should be common place/ and at the end of the day the “CGM” and the proformance of AFREZZA will tell the no tail (pun intended) how can the medical community dispute the time in range numbers mannkind puts up if used correctly. GLTA.
|
|
|
Post by akemp3000 on Apr 5, 2018 13:27:21 GMT -5
Let's go with yes and start the climb...for real ...and it's understood Good Friday might have had an effect.
|
|
|
Post by whale1r1 on Apr 5, 2018 15:38:35 GMT -5
The question that should be asked is why the Alfred Mann Foundation is refusing to assist the company with "key relationships". Specifically the foundation has given an enormous amount of money to John Hopkins and the Endos at this facility has made no effort to meet with Afrezza sales reps. Instead of the foundation taking the issue head on, they make excuses as to why they can't help.
If afrezza is going to be successful this needs to. W addressed. I will not be able to attend but if someone could take this issue head on with the board that would be appreciated. By the way Kent Kresa is on the Alfred Mann foundation board.
|
|
|
Post by lojothehus on Apr 5, 2018 16:55:07 GMT -5
Let's go with yes and start the climb...for real ...and it's understood Good Friday might have had an effect. I am with you all the way, I am guessing 522.
|
|
|
Post by kite on Apr 5, 2018 16:56:02 GMT -5
Let's go with yes and start the climb...for real ...and it's understood Good Friday might have had an effect. I am with you all the way, I am guessing 522. My guess will be 507!
|
|